Category Archives: Prostate Cell

No account yet? Register

Review

Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review

Researchers review the current status of immunotherapy, including new discoveries and precision approaches to prostate cancer, and discuss future directions in the continuously evolving landscape of immunotherapy.

[International Journal of Molecular Sciences]

Continue reading “Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review”

No account yet? Register

Continue reading “Chelerythrine Suppresses Proliferation and Metastasis of Human Prostate Cancer Cells via Modulating MMP/TIMP/NF-κB System”

Chelerythrine Suppresses Proliferation and Metastasis of Human Prostate Cancer Cells via Modulating MMP/TIMP/NF-κB System

The addition of chelerythrine significantly inhibited the proliferation of androgen-independent prostate cancer DU145 and PC-3 cells at the concentration of 5 and 10 μM, but not on androgen-dependent prostate cancer LNCaP cells as well as normal prostate epithelial cell line PrEC cells.

[Molecular and Cellular Biochemistry]

Abstract

Continue reading “ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics”

No account yet? Register

industry & policy

ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics

ORIC Pharmaceuticals, Inc. announced it has entered into an exclusive worldwide license agreement with Mirati Therapeutics, Inc. ORIC will have exclusive worldwide rights for the development activities and commercialization of a small molecule allosteric inhibitor program directed towards the polycomb repressive complex 2, a validated oncogenic target across several cancers with promising therapeutic potential in prostate cancer, among other indications.

[ORIC Pharmaceuticals, Inc.]

Press Release

No account yet? Register

Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells

Scientists developed curcumin nanoparticles and evaluated their cytotoxicity in docetaxel (DTX)-resistant castration-resistant prostate cancer (CRPC) cells for the treatment of DTX-resistant CRPC.

[Biomedicines]

Continue reading “Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells”

No account yet? Register

Predicting New Drug Indications for Prostate Cancer: The Integration of an In Silico Proteochemometric Network Pharmacology Platform with Patient‐Derived Primary Prostate Cells

Researchers integrated a computational proteochemometric systems network pharmacology platform, DrugGenEx‐Net, with primary, continuous cultures of conditionally reprogrammed normal and prostate cancer (PCa) cells derived from treatment‐naive patients with primary PCa.

[Prostate]

Continue reading “Predicting New Drug Indications for Prostate Cancer: The Integration of an In Silico Proteochemometric Network Pharmacology Platform with Patient‐Derived Primary Prostate Cells”

No account yet? Register

Quercetin–Resveratrol Combination for Prostate Cancer Management in TRAMP Mice

Scientists determined the effects of grape antioxidants quercetin and/or resveratrol against prostate cancer in the transgenic adenocarcinoma of mouse prostate (TRAMP)-model in prevention and intervention settings.

[Cancers]

Continue reading “Quercetin–Resveratrol Combination for Prostate Cancer Management in TRAMP Mice”

No account yet? Register

The Prostaglandin Synthases, COX-2 and L-PGDS, Mediate Prostate Hyperplasia Induced by Low-Dose Bisphenol A

In vitro studies showed that low-dose bisphenol A promoted the proliferation of human prostate fibroblasts and epithelial cells, and significantly upregulated the expression of cyclooxygenase-2 (COX-2) and L-PGDS in the cells.

[Scientific Reports]

Continue reading “The Prostaglandin Synthases, COX-2 and L-PGDS, Mediate Prostate Hyperplasia Induced by Low-Dose Bisphenol A”

No account yet? Register

The Spectrum of Design Solutions for Improving the Activity-Selectivity Product of Peptide Antibiotics against Multidrug-Resistant Bacteria and Prostate Cancer PC-3 Cells

Scientists hypothesized that designed peptides with a wide spectrum of selective antimicrobial activity will also have anticancer activity, and tested this hypothesis with newly designed peptides.

[Molecules]

Continue reading “The Spectrum of Design Solutions for Improving the Activity-Selectivity Product of Peptide Antibiotics against Multidrug-Resistant Bacteria and Prostate Cancer PC-3 Cells”

No account yet? Register

Abstract Graphical Abstract

Mitochondrial Functional and Structural Impairment Is Involved in the Antitumor Activity of δ-Tocotrienol in Prostate Cancer Cells

The authors investigated whether δ-tocotrienol (δ-TT) might exert its activity by impairing mitochondrial functions. They demonstrated that, in PC3 and DU145 cells, δ-TT impairs mitochondrial respiration and structural dynamics.

[Free Radical Biology and Medicine]

Continue reading “Mitochondrial Functional and Structural Impairment Is Involved in the Antitumor Activity of δ-Tocotrienol in Prostate Cancer Cells”

Continue reading “Twitter Account of Embattled #MeTooSTEM Founder Suspended”

No account yet? Register

industry & policy

Twitter Account of Embattled #MeTooSTEM Founder Suspended

Twitter has suspended the account of MeTooSTEM founder BethAnn McLaughlin after allegations emerged that the former Vanderbilt University neuroscientist fabricated the Twitter account of an apparently nonexistent female Native American anthropologist at Arizona State University who had claimed to be an anonymous victim of sexual harassment by a Harvard professor.

[ScienceInsider]

Press Release

No account yet? Register

Continue reading “Combination Therapy with Androgen Receptor N‐Terminal Domain Antagonist EPI‐7170 and Enzalutamide Yields Synergistic Activity in AR‐V7‐Positive Prostate Cancer”

Combination Therapy with Androgen Receptor N‐Terminal Domain Antagonist EPI‐7170 and Enzalutamide Yields Synergistic Activity in AR‐V7‐Positive Prostate Cancer

Scientists evaluated the antitumor effect of a next‐generation analog of ralaniten as a monotherapy or in combination with enzalutamide in prostate cancer cells that express AR‐V7 that were resistant to enzalutamide.

[Molecular Oncology]

Abstract